Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 58 points (-0.4%) at 15,461 as of Wednesday, Aug. 7, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 785 issues advancing vs. 2,161 declining with 94 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.4%. Top gainers within the industry include Santarus ( SNTS), up 8.5%, Biomarin Pharmaceutical ( BMRN), up 2.1%, Celgene Corporation ( CELG), up 1.4%, Amgen ( AMGN), up 1.8% and Sanofi ( SNY), up 0.8%. A company within the industry that fell today was Biogen Idec ( BIIB), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.30 (0.6%) to $51.63 on average volume. Thus far, 1.2 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $51.57-$52.01 after having opened the day at $51.63 as compared to the previous trading day's close of $51.33.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $128.1 billion and is part of the health care sector. Shares are up 19.3% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $0.76 (1.0%) to $78.09 on light volume. Thus far, 440,046 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $76.80-$78.36 after having opened the day at $77.31 as compared to the previous trading day's close of $77.33.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.4 billion and is part of the health care sector. Shares are up 84.6% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.35 (0.9%) to $38.80 on light volume. Thus far, 1.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $38.35-$38.99 after having opened the day at $38.38 as compared to the previous trading day's close of $38.45.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.5 billion and is part of the health care sector. Shares are up 3.0% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.65 (0.7%) to $96.37 on average volume. Thus far, 1.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $95.35-$97.60 after having opened the day at $96.78 as compared to the previous trading day's close of $95.72.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $31.7 billion and is part of the health care sector. Shares are up 60.1% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Merck ( MRK) is up $0.27 (0.6%) to $48.71 on light volume. Thus far, 3.8 million shares of Merck exchanged hands as compared to its average daily volume of 17.6 million shares. The stock has ranged in price between $48.35-$48.75 after having opened the day at $48.35 as compared to the previous trading day's close of $48.44.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $146.5 billion and is part of the health care sector. Shares are up 18.3% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Merck a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Stocks Finish Higher After Release of Fed Minutes

Stocks Finish Higher After Release of Fed Minutes

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation